The Incidence of Linezolid-induced Thrombocytopenia (LIT) in Critically Ill Patients, the Risk Factors for LIT

Helwan University

Status: Enrolling

Conditions: Thrombocytopenia; Drugs

Treatments: Drug: Linezolid 600 mg

Study type: Observational

Funder types: Other

Identifiers

NCT05944445

11041989

Details and patient eligibility

About

• To identify the incidence of LIT among critically ill patients, as limited studies have only addressed this population.
• To evaluate the impact of several factors on the incidence of LIT, the time to onset of LIT, and the time to recovery of platelets.
• To study the effect of concurrent medications (enoxaparin, unfractinated heparin, piperacillin, carbapenems, tigecycline, fluconazole or voriconazole, digoxin, amiodarone, acetaminophen, tirofiban, statins, and antiepileptics) frequently used in critically ill patients on the incidence of LIT.
• To investigate the impact of possible medications with an antioxidant effect on the prevention of LIT.
• To assess the impact of LIT on composite end point (mortality, bleeding, and length of stay)

Enrollment: 310 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All adult patients, age > or = 18 years old, admitted to the ICU with different indications.
• candidates for intravenous linezolid therapy for > or =1 day.

Exclusion criteria

• Taking any myelosuppressive drug.
• Baseline platelets < 50000.
• Patients with hematological malignancy.
• COVID-19 patients.
• Patients with immune thrombocytopenia

Trial design

310 participants in 1 patient group

Single arm group

Description:

Adult critically ill patients admitted to ICU for different indications

Treatment:

Drug: Linezolid 600 mg